2011Diluted net income per share on a GAAP basis$
.63Share-based compensation expense:- Cost of product sales0.010.010.010.01- Selling, general and administrative0.060.040.110.08- Research and development0.030.020.050.03Amortization of purchased intangibles- Cost of product sales0.030.030.070.06- Selling, general and administrative0.01-0.020.01- Research and development----Levitronix Medical FMV inventory adjustments--0.01-Levitronix Medical transaction costs-0.02-0.02Income tax effect of non-GAAP adjustments(0.04)(0.04)(0.09)(0.07)Diluted net income per share on a non-GAAP basis$
.77 Three Months Ended Six Months Ended June 30,
2011Shares used to compute diluted net income per share reconciliationShares used in calculation of diluted net income per share -- GAAP59,51863,21359,51364,590Weighted average unvested restricted stock awards (1)-9125130Shares used in calculation of diluted net income per share -- non-GAAP59,51863,30459,53864,720(1)
The company adopted the two-class method in calculating net income per share on a GAAP basis, which excludes the weighted average unvested restricted stock awards outstanding
|SOURCE Thoratec Corporation|
Copyright©2012 PR Newswire.
All rights reserved